Qiming Venture Partners and 50+ portfolio companies named to 2025 Future Healthcare 100 list
These rankings and reports aim to document the year's industry breakthroughs and reveal the growth patterns of listed companies and evolving industry trends, offering a reference for healthcare enterprises and entrepreneurs.
Recently, the 2025 Future Healthcare 100 list and corporate growth report were officially released. The list and report aim to document the year's industry breakthroughs, reveal the growth patterns of listed companies and trends in industrial transformation, and provide reference for healthcare enterprises and entrepreneurs.
The 2025 Future Healthcare 100 list comprises the main Future Healthcare 100 list, the Listed Companies Innovation Ranking, and the Future Healthcare 100 Innovation Awards. Qiming Venture Partners and its portfolio companies received multiple awards.
In the institutional categories, Qiming Venture Partners, William Hu (Managing Partner at Qiming Venture Partners), and Kan Chen (Partner at Qiming Venture Partners and Co-Head of Healthcare) won three awards.
Qiming Venture Partners
was named
Healthcare Leader Investment Institution of the Year
William Hu, Managing Partner at Qiming Venture Partners
was named
Healthcare Leader Investor of the Year
Kan Chen, Partner at Qiming Venture Partners and Co-Head of Healthcare
was named
Healthcare Excellence Investor of the Year
Qiming Venture Partners portfolio companies Shukun Technology, Cornerstone Robotics, Astrolab Diagnostics, Dilo Medical, Northsea Medical, Haosi Biotech, Pulnovo Medical, Topeye Med, Dingke Medical, Wanzhong Yixin, Jialiang Medical, Insilico Medicine, Belief BioMed, Ark Biosciences, LaNova Medicines, MediLink Therapeutics, Sanegene Bio, Glorium Biotech, BHC Therapeutics, Ticoon Bio, Shize Biotech, Ze'an Biopharmaceutical, Epigenic Therapeutics, Yuanxin Technology, Fukangkang, YourHealth, Liangyihui, Zhilan Health, Zuoyi Technology, Xiaoniao Health, Huimei Technology, BioLink, Inscinstech, Taihe Weiye, Stackless Data, M20 Genomics, TetraMed, Thorough Future, Zai Lab (NASDAQ: ZLAB, 09688.HK), Gan & Lee Pharmaceuticals (603087.SH), SinoCellTech (688520.SH), Tigermed (300347.SZ, 03347.HK), MicroPort EP MedTech (688617.SH), UroGen Pharma (688176.SH), Lanmu Medical, ShengZhe Medical, CANbridge Pharmaceuticals (01228.HK), Sinotau Pharmaceutical, Rainkine Bio, and Nopo Bio were selected for the list.
Shukun Technology, Cornerstone Robotics, Astrolab Diagnostics, Dilo Medical, Northsea Medical, Haosi Biotech, Pulnovo Medical, Topeye Med, Dingke Medical, Wanzhong Yixin, Jialiang Medical, and others
were selected for
China's Top 100 Innovative Devices and Intelligent Manufacturing
Insilico Medicine, Belief BioMed, Ark Biosciences, LaNova Medicines, MediLink Therapeutics, Sanegene Bio, Glorium Biotech, BHC Therapeutics, Ticoon Bio, Shize Biotech, Ze'an Biopharmaceutical, Epigenic Therapeutics
were selected for
China's Top 100 Innovative Pharmaceuticals and Biological Products
Yuanxin Technology, Fukangkang, YourHealth, Liangyihui, Zhilan Health, Zuoyi Technology, Xiaoniao Health
were selected for
China's Top 100 Healthcare and Health Innovation Services
Huimei Technology, BioLink, Inscinstech, Taihe Weiye, Stackless Data, M20 Genomics, TetraMed, Thorough Future
were selected for
China's Top 100 Healthcare Industry Chain Services
Zai Lab, Gan & Lee Pharmaceuticals, SinoCellTech, Tigermed, MicroPort EP MedTech, UroGen Pharma
were selected for
Healthcare Listed Companies Innovation Top 100
Insilico Medicine, Yuanxin Technology
were named
Enterprise of the Year
Ze'an Biopharmaceutical
was named
Rising Enterprise of the Year
Northsea Medical · Intravascular Ultrasound System (the first domestically developed IVUS approved under EU MDR)
Cornerstone Robotics · Sentire® Laparoscopic Surgical Robot (a fully self-developed laparoscopic surgical robot system)
Lanmu Medical · AqueFish® Glaucoma Schlemm's Canal Drainage Stent (China's first original minimally invasive glaucoma treatment stent)
ShengZhe Medical · SA100 Ultrasonic High-Frequency Soft Tissue Cutting and Hemostasis Device (the first domestic device integrating ultrasonic and advanced bipolar energy)
were named
Best Smart Medical Device Technology Innovation Product
Ark Biosciences · Ziresovir Enteric-Coated Capsules (a global "first-in-class" RSV-specific antiviral drug)
CANbridge Pharmaceuticals · Velaglucerase Alfa for Injection (China's first independently developed and clinically applied Gaucher disease enzyme replacement innovative drug)
were named
Best Biotechnology Innovation Product
Topeye Med · Ophthalmic Surgical Microscope (the world's first intelligent surgical microscope with intraoperative real-time 3D OCT navigation)
Sinotau Pharmaceutical · Oweining® Florbetaben [18F] Injection (China's first approved Aβ-PET imaging agent for Alzheimer's disease diagnosis)
Gan & Lee Pharmaceuticals · Bofan Glutide (potentially the world's first biweekly GLP-1RA formulation)
were selected for
Value Product/Solution List
Rainkine Bio · Respacio® Radiotherapy Protective Hydrogel (the world's first hydrogel product for cervical cancer radiotherapy protection)
was named
Most Clinically Followed Product
Pulnovo Medical · PADN Interventional Product for Pulmonary Hypertension (China's first globally approved interventional treatment for pulmonary arterial hypertension)
Wanzhong Yixin · NGS Semiconductor Chip Gene Sequencer (the industry's fastest ISFET chip high-speed electronic gene sequencer)
were named
Most VC-Followed Product
Liu Heng, Co-founder and General Manager of Ticoon Bio Yang Xi, Co-founder and CEO of Nopo Bio
were named
Healthcare Innovation Entrepreneurs of the Year
· 2025 Future Healthcare 100 Main List
This list targets non-listed companies in the healthcare sector. Based on the VB100 value assessment model, it follows a process of enterprise self-nomination, VB100 review committee evaluation, cross-review by supporting institutions, and final review by the expert committee. From four sectors (innovative devices and intelligent manufacturing, innovative pharmaceuticals and biological products, healthcare and health innovation services, and healthcare industry chain services), it selects the top 100 innovative enterprises by valuation. Beyond valuation, the organizer supplements with research on candidates' growth and annual performance across four primary indicators — human resources, knowledge resources, key partner resources, and market performance — comprising 17 secondary indicators.
· Listed Companies Innovation Ranking
This ranking targets listed companies in the healthcare sector. Built around six key metrics — market capitalization and annual growth, revenue and annual growth, and R&D expenses and annual growth — the ranking aims to reveal corporate capital value and strategic innovation, market value and commercial innovation, and technology value and product innovation through data analysis. It deeply examines enterprises' innovation value and growth trajectory to identify benchmark companies with high innovation capacity and strong growth performance driven by innovation.
· Future Healthcare 100 Innovation Awards
The Future Healthcare 100 Innovation Awards evaluate institutions, enterprises, parks, individuals, and products in the healthcare sector. The awards focus on candidates' annual value performance and innovation breakthroughs during the review period; for individual candidates, the assessment centers on annual leadership performance, industry influence, visibility, and insight during the review period.
VBData notes that innovative device and intelligent manufacturing companies on the list concentrate in imaging and therapeutic equipment, cardiovascular high-value consumables, surgical robots, IVD, and other hot sectors. Among innovative pharmaceutical and biological product companies, a cohort of internationally competitive Chinese innovative pharmaceutical enterprises with early global expansion is beginning to emerge.
Unicorn companies (by valuation) that appeared on both last year's and this year's lists are mostly distributed across medical imaging, AI drug discovery, cell and gene therapy, specialty hospital chains, and R&D manufacturing outsourcing.
Over the past year, China's healthcare industry has delivered an inspiring innovation report card: 43 domestic innovative drugs and 66 innovative medical devices received approval, hitting record highs; Chinese innovative drug license-out transaction totals reached new breakthroughs, leaving a distinct Chinese mark on the global pharmaceutical innovation map. More notably, the density of industry collaboration has significantly increased, cross-domain technology integration is accelerating, and the innovation ecosystem is gaining vitality through restructuring.
Behind this impressive performance lies the perseverance and breakthroughs of countless healthcare innovators at critical junctures. When traditional models face challenges, true innovators are building momentum: some are digging deep into underlying technologies hoping to achieve breakthroughs; some are reconstructing business models to open new payment pathways; others are embracing globalization to bring Chinese solutions to the world stage.
Source | VBData
Past Reviews
Qiming Honors | Qiming Venture Partners and Nearly 50 Portfolio Companies Win Multiple Awards in 2023 Future Healthcare 100 Series Qiming Stars | Over 20 Qiming Venture Partners Portfolio Companies Selected for 2025 China Future Unicorn Top 100 and Other Lists Qiming Headlines | Qiming Venture Partners and Portfolio Companies Win Multiple Awards Including ChinaVenture 2024 China Best VC Firm TOP5
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative enterprises, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ: WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, and Biren Technology.